Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Myovant Sciences (MYOV : NYSE)

• Company Description    Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. Number of Employees: 579

• Price / Volume Information    Yesterday's Closing Price: $10.08 Daily Weekly Monthly 20 Day Moving Average: 999,831 shares Shares Outstanding: 95.33 (millions) Market Capitalization: $960.95 (millions) Beta: 2.79 52 Week High: $27.43 52 Week Low: $7.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.77% 19.14% 12 Week -22.22% -14.49% Year To Date -35.26% -20.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR - LONDON,X0 SW1Y 4LB GBR ph: 44-20-7400-3351 fax: - investors@myovant.com None

• General Corporate Information    Officers David Marek - Principal Executive Officer Myrtle Potter - Chairman Uneek Mehra - Principal Financial Officer Terrie Curran - Director Mark Guinan - Director Peer Information Myovant Sciences (CORR.) Myovant Sciences (RSPI) Myovant Sciences (CGXP) Myovant Sciences (BGEN) Myovant Sciences (GTBP) Myovant Sciences (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G637AM102 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/22 Next Expected EPS Date: 07/27/22 Share - Related Items Shares Outstanding: 95.33 Most Recent Split Date: (:1) Beta: 2.79 Market Capitalization: $960.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/27/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.16 EPS Growth vs. Year Ago Period: 29.21% vs. Previous Quarter: 7.35% Sales Growth vs. Year Ago Period: 133.96% vs. Previous Quarter: 5.74% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -32.54 12/31/21 - -33.33 09/30/21 - -32.82 Current Ratio 03/31/22 - 1.95 12/31/21 - 2.14 09/30/21 - 2.44 Quick Ratio 03/31/22 - 1.92 12/31/21 - 2.11 09/30/21 - 2.42 Operating Margin 03/31/22 - -89.18 12/31/21 - -115.18 09/30/21 - -164.51 Net Margin 03/31/22 - -89.18 12/31/21 - -115.18 09/30/21 - -164.51 Pre-Tax Margin 03/31/22 - -87.00 12/31/21 - -114.16 09/30/21 - -164.13 Book Value 03/31/22 - -4.97 12/31/21 - -4.60 09/30/21 - -4.10 Inventory Turnover 03/31/22 - 1.87 12/31/21 - 1.67 09/30/21 - 1.22 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©